Phase II Trial of Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma.

Trial Profile

Phase II Trial of Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 12 May 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
    • 14 May 2015 Planned End Date changed to 1 Aug 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top